Want to see NGNE full AI Analyst Report?
NGNE Stock Chart & Stats
$40.84
-$0.67(-1.88%)
At close: 4:00 PM EDT
$40.84
-$0.67(-1.88%)
Day’s Range― - ―
52-Week Range$15.93 - $43.66
Previous Close$34.9
Volume161.73K
Average Volume (3M)352.17K
Market Cap
$508.29M
Enterprise Value$492.21M
Total Cash (Recent Filing)$225.39M
Total Debt (Recent Filing)$8.35M
Price to Earnings (P/E)―
Beta3.17
Next Earnings
Nov 23, 2026EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.51
Shares Outstanding20,011,381
10 Day Avg. Volume404,780
30 Day Avg. Volume352,165
Financial Highlights & Ratios
PEG Ratio5.20
Price to Book (P/B)1.65
Price to Sales (P/S)0.00
P/FCF Ratio-5.57
Enterprise Value/Market Cap0.97
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-26.07
Enterprise Value/Ebitda-4.56
Forecast
1Y Price Target
$80.17Price Target Upside96.29% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-5.64
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company has modest debt relative to its equity base, reducing near-term solvency pressure and preserving financial flexibility. This comparatively conservative capital structure may give Neurogene more room to fund clinical development without the immediate burden of substantial interest obligations or refinancing exposure.
Focused Genetic-Medicine PipelineA focused pipeline built around genetic medicines addresses serious neurological disorders where targeted biological approaches may have meaningful clinical relevance. Concentration on genetically defined diseases can support a clear development strategy and align research efforts with identifiable patient populations over the medium term.
Central Nervous System FocusThe company’s emphasis on central nervous system gene delivery establishes a consistent therapeutic focus rather than a broadly diversified discovery portfolio. Continued work in this specialized area could build development expertise and maintain strategic coherence across programs targeting severe neurological conditions.
Bears Say
Pre-Revenue LossesNeurogene remains pre-revenue while losses have expanded substantially, leaving current operations dependent on continued investment before commercial products generate offsetting income. The absence of meaningful revenue makes profitability highly contingent on successful clinical progress and eventual commercialization of its pipeline.
Worsening Cash BurnIncreasing operating and free cash outflows indicate that the company’s funding requirements are rising as development spending continues. Without a step-change in revenue or spending discipline, sustained cash consumption could require additional financing and may constrain the pace or scope of future clinical investment.
Shrinking Equity BaseThe declining equity base shows that ongoing losses are consuming shareholder capital rather than compounding it. Persistently negative returns on equity reinforce the challenge of converting research investment into financial returns, while continued erosion could reduce the balance-sheet cushion available for long-duration development programs.
Neurogene News
NGNE FAQ
What was Neurogene’s price range in the past 12 months?
Neurogene lowest stock price was $15.93 and its highest was $43.66 in the past 12 months.
What is Neurogene’s market cap?
Neurogene’s market cap is $508.29M.
When is Neurogene’s upcoming earnings report date?
Neurogene’s upcoming earnings report date is Nov 23, 2026 which is in 30 days.
How were Neurogene’s earnings last quarter?
Neurogene released its earnings results on Aug 11, 2026. The company reported -$1.53 earnings per share for the quarter, missing the consensus estimate of -$1.423 by -$0.107.
Is Neurogene overvalued?
According to Wall Street analysts Neurogene’s price is currently Undervalued.
Does Neurogene pay dividends?
Neurogene does not currently pay dividends.
What is Neurogene’s EPS estimate?
Neurogene’s EPS estimate is -1.36.
How many shares outstanding does Neurogene have?
Neurogene has 20,011,381 shares outstanding.
What happened to Neurogene’s price movement after its last earnings report?
Neurogene reported an EPS of -$1.53 in its last earnings report, missing expectations of -$1.423. Following the earnings report the stock price went down -2.052%.
Which hedge fund is a major shareholder of Neurogene?
Currently, no hedge funds are holding shares in NGNE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neurogene Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$80.17 (96.29% Upside)
$80.17 (96.29% Upside)
Blogger Sentiment
Neutral
NGNE Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 252.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 5.2%
Last 30 Days ▼ 5.2%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.01%
12-Months-Change
Fundamentals
Return on Equity
-45.11%
Trailing 12-Months
Asset Growth
-17.81%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Neurogene
Neurogene Inc. is dedicated to engineering transformative genetic treatments for individuals and their families grappling with debilitating neurological conditions. Its current pipeline prominently features two key investigational therapies: NGN-401, an AAV9 gene therapy specifically targeting Rett syndrome, and NGN-101, which is being developed to address neuronal ceroid lipofuscinosis subtype 5 (Batten disease). The company's operations are based in New York, New York.
NGNE Stock 12 Month Forecast
Average Price Target
$80.17
▲(96.29% Upside)
Technical Analysis
RegenXBio
―
Wave Life Sciences
―
Solid Biosciences
―
4D Molecular Therapeutics
―
Lexeo Therapeutics, Inc.
―
Ownership Overview
7.36% Insiders
6.59% Mutual Funds
54.56% Other Institutional Investors
19.55% Public Companies and
Individual Investors